Mitchall G. Clark, EVP & Chief R & QA Officer at Atara Biotherapeutics, Inc. (ATRA), sold 100,203 shares at $36.43 ($3.8M) on 2018-03-27, disclosed to the SEC on 2018-03-28.
Open-market sale of $3.8M ATRA by EVP & Chief R & QA Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.43 | 22,794 | $830K | 21.9% |
| 2 | $37.10 | 31,356 | $1.2M | 30.7% |
| 3 | $38.23 | 29,980 | $1.1M | 30.2% |
| 4 | $39.53 | 2,170 | $86K | 2.3% |
| 5 | $40.40 | 2,800 | $113K | 3.0% |
| 6 | $41.10 | 11,103 |
| $456K |
| 12.0% |
| Total | $37.87 avg | 100,203 | $3.8M | 100% |
| Filing → |
| ATRA | SELL | 2018-04-03 | $898K | — | Filing → |
| ATRA | SELL | 2017-11-17 | $47K | — | Filing → |
| ATRA | SELL | 2017-08-17 | $43K | — | Filing → |